Literature DB >> 27457632

Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions.

Kerry J Welsh1, M Sue Kirkman2, David B Sacks3.   

Abstract

Entities:  

Year:  2016        PMID： 27457632      PMCID： PMC4955935          DOI： 10.2337/dc15-2727

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  94 in total

Review 1.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

2.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Clin Chem       Date:  2011-05-26       Impact factor: 8.327

3.  Specific glycation of albumin depends on its half-life.

Authors:  E D Schleicher; B Olgemöller; E Wiedenmann; K D Gerbitz
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

4.  Fructosamine Test-Plus, a modified fructosamine assay evaluated.

Authors:  J Baker; P Metcalf; R Scragg; R Johnson
Journal:  Clin Chem       Date:  1991-04       Impact factor: 8.327

5.  Glycated albumin is low in obese, type 2 diabetic patients.

Authors:  Yumi Miyashita; Rimei Nishimura; Aya Morimoto; Toru Matsudaira; Hironari Sano; Naoko Tajima
Journal:  Diabetes Res Clin Pract       Date:  2007-04-16       Impact factor: 5.602

6.  Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma.

Authors:  Feliciano Priego-Capote; Alexander Scherl; Markus Müller; Patrice Waridel; Frédérique Lisacek; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2009-11-06       Impact factor: 5.911

7.  Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products.

Authors:  J V Valencia; M Mone; C Koehne; J Rediske; T E Hughes
Journal:  Diabetologia       Date:  2004-05-01       Impact factor: 10.122

Review 8.  Emerging principles for the therapeutic exploitation of glycosylation.

Authors:  Martin Dalziel; Max Crispin; Christopher N Scanlan; Nicole Zitzmann; Raymond A Dwek
Journal:  Science       Date:  2014-01-03       Impact factor: 47.728

9.  The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study.

Authors:  Trevor J Orchard; Timothy J Lyons; Patricia A Cleary; Barbara H Braffett; John Maynard; Catherine Cowie; Rose A Gubitosi-Klug; Jeff Way; Karen Anderson; Annette Barnie; Stephan Villavicencio
Journal:  Diabetes Care       Date:  2013-06-28       Impact factor: 19.112

10.  Response to comments on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.

Authors:  Elizabeth Selvin; Josef Coresh; Marc K Halushka
Journal:  Diabetes       Date:  2013-10       Impact factor: 9.461
View more
  43 in total

1.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading.

Authors:  Roy W Beck; Crystal G Connor; Deborah M Mullen; David M Wesley; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2017-08       Impact factor: 19.112

2.  Monitoring Glycemic Control in End-Stage Renal Disease: What Should Be Measured?

Authors:  Elizabeth Selvin; David B Sacks
Journal:  Clin Chem       Date:  2016-12-14       Impact factor: 8.327

3.  Establishment of Community-Based Reference Intervals for Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol.

Authors:  Elizabeth Selvin; Bethany Warren; Xintong He; David B Sacks; Amy K Saenger
Journal:  Clin Chem       Date:  2018-02-07       Impact factor: 8.327

4.  Should we continue to use the 75-g OGTT to diagnose diabetes?

Authors:  Maria Tomkins; Diarmuid Smith
Journal:  Ir J Med Sci       Date:  2020-05       Impact factor: 1.568

5.  COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging Beyond Topics.

Authors:  J Saban-Ruiz; D Ly-Pen
Journal:  J Nutr Health Aging       Date:  2020-05-12       Impact factor: 4.075

6.  Physician Knowledge of Human Genetic Variation, Beliefs About Race and Genetics, and Use of Race in Clinical Decision-making.

Authors:  Sherrill L Sellers; Brooke A Cunningham; Vence L Bonham
Journal:  J Racial Ethn Health Disparities       Date:  2018-06-20

7.  Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?

Authors:  Chiara Fabris; Lutz Heinemann; Roy Beck; Claudio Cobelli; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2020-07       Impact factor: 6.118

8.  The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring.

Authors:  Pamela R Kushner; Davida F Kruger
Journal:  Clin Diabetes       Date:  2020-10

9.  Application of a near-infrared laser tweezers Raman spectroscopy system for label-free analysis and differentiation of diabetic red blood cells.

Authors:  Jinyong Lin; Lingdong Shao; Sufang Qiu; Xingwu Huang; Mengmeng Liu; Zuci Zheng; Duo Lin; Yongliang Xu; Zhihua Li; Yao Lin; Rong Chen; Shangyuan Feng
Journal:  Biomed Opt Express       Date:  2018-02-02       Impact factor: 3.732

10.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.